Literature DB >> 8095148

Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.

C Mura1, N Gerard, M Vincent-Viry, M M Galteau, E Jacqz-Aigrain, R Krishnamoorthy.   

Abstract

1. Cytochrome P450 debrisoquine (CYP2D6) activity is polymorphic and under genetic control. Most Caucasians are extensive metabolizers, but 5%-10% are poor metabolizers. 2. Restriction fragment length polymorphism analysis of the CYP2D6 locus identifies a 29kb XbaI fragment, either normal (D6-wt) or mutated, and three mutated XbaI alleles (44kb, 11.5kb and 16 + 9kb). The 44kb allele was initially considered as a poor metabolizer allele owing to a D6-B mutation, but cases of 44kb allele not carrying the D6-B, and therefore potentially functional, have been found. The degree of molecular heterogeneity of this allele was investigated by phenotype and genotype analysis of families. 3. Thirty-one French Caucasian families, representing 117 individuals, possessing at least one 44kb allele in each family were selected. Phenotypes were determined using dextromethorphan, and the XbaI, NcoI and BamH1 RFLPs of 42 independent chromosomes were analyzed. 4. 80% of the XbaI 44kb alleles carried the CYP2D6-B mutation and had an additional NcoI fragment (12.5kb or 4.8kb). The remaining 20% did not carry the CYP2D6-B or A mutations and had no extra NcoI fragment. 5. Information on three families demonstrated that 44kb alleles not carrying the CYP2D6-B mutation were associated with the extensive metabolizer phenotype. 6. We conclude that a substantial percentage of XbaI 44kb alleles is associated with a functional CYP2D gene, and therefore, that the XbaI 44kb allele is not consistently a poor metaboliser allele.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095148      PMCID: PMC1381508          DOI: 10.1111/j.1365-2125.1993.tb05681.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.

Authors:  M L Dahl; I Johansson; M P Palmertz; M Ingelman-Sundberg; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1992-01       Impact factor: 6.875

Review 2.  The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.

Authors:  U A Meyer; R C Skoda; U M Zanger
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

Authors:  S Kimura; M Umeno; R C Skoda; U A Meyer; F J Gonzalez
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

4.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Direct determination of dextromethorphan and its three metabolites in urine by high-performance liquid chromatography using a precolumn switching system for sample clean-up.

Authors:  N Motassim; D Decolin; T Le Dinh; A Nicolas; G Siest
Journal:  J Chromatogr       Date:  1987-11-27

6.  Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors:  E Jacqz; H Dulac; H Mathieu
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  P450 genes: structure, evolution, and regulation.

Authors:  D W Nebert; F J Gonzalez
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

8.  Genetically determined oxidation capacity and the disposition of debrisoquine.

Authors:  T P Sloan; R Lancaster; R R Shah; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

9.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

Authors:  R C Skoda; F J Gonzalez; A Demierre; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  4 in total

1.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

Authors:  R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 2.  Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism.

Authors:  E Jacqz-Aigrain; S Panserat; L Sica; R Krishnamoorthy
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacoz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

4.  DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.

Authors:  C Mura; S Panserat; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.